I think what Dalhousie is starting is really a phase one study, which is exactly to look at what you're talking about in terms of safety.
I think people have been in high gear about bringing the pre-human candidate vaccine to first-in-human trials because that's when it becomes very important.
It would be too quick if we were launching a phase three study or we were going to make this vaccine available for public use, but to have it in phase one, I think is perfect.